Compare MobilEye Global Inc (MBLY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $5.97B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: MobilEye Global Inc is far larger — about 6.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MBLY | MRVI | |
|---|---|---|
Market Cap | $5.97B | $972.90M |
Volume | 6,124,531 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.33 | $9.00 |
52-Week Low | $6.56 | $2.83 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.53B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.02, up 2.63% with recent earnings beats but faces bearish technical signals and significant net losses. The stock shows strong institutional support with 57.7% analyst buy ratings and a $10.77 consensus target, yet profitability remains challenged with a -201.5% net margin. Recent news highlights ADAS business momentum and autonomous vehicle expansion opportunities.
The outlook presents a high-risk opportunity with potential upside from autonomous driving adoption, but investors face substantial execution risks and ongoing losses. Key catalysts include Porsche launch progress and robotaxi developments, while competitive pressures and cash flow volatility remain significant concerns for near-term performance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
